Scilex Holding (SCLXW) Non Operating Income (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Non Operating Income of -$13.5 million in Q1 2026, down 120.74% quarter-over-quarter from $65.0 million in Q4 2025, and down 841.53% on a YoY basis from $1.8 million in Q1 2025.
Scilex Holding (SCLXW) Non Operating Income (2022 - 2026) Analysis & Trends
Scilex Holding's Non Operating Income history runs 5 years deep, the most recent figure standing at -$13.5 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 841.53% year-over-year to -$13.5 million; the TTM figure through Mar 2026 stood at -$43.3 million (down 350.33% YoY), while the FY2025 annual figure was -$28.0 million, down 364.64% from the prior year.
- Non Operating Income was -$13.5 million for Q1 2026 at Scilex Holding, down from $65.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $65.0 million in Q4 2025 to a low of -$71.3 million in Q3 2025.
- Historically, Non Operating Income has averaged -$538882.4 across 5 years, with a median of -$3.1 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Non Operating Income surged 817.88% in 2024, then sank 841.53% in 2026.
- A 5-year view of Non Operating Income shows it stood at $1.9 million in 2022, then sank by 260.94% to -$3.1 million in 2023, then soared by 817.88% to $21.9 million in 2024, then surged by 196.53% to $65.0 million in 2025, then sank by 120.74% to -$13.5 million in 2026.
- The last three Non Operating Income figures came in at -$13.5 million (Q1 2026), $65.0 million (Q4 2025), and -$71.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.48 Mn |
| Dec 31, 2025 | 64.99 Mn |
| Sep 30, 2025 | -71.31 Mn |
| Jun 30, 2025 | -23.52 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 21.92 Mn |
| Sep 30, 2024 | 15.53 Mn |
| Jun 30, 2024 | -21.96 Mn |
| Mar 31, 2024 | -4.90 Mn |
| Dec 31, 2023 | -3.05 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | -3.84 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | 1.90 Mn |
| Sep 30, 2022 | 32.11 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | 3.03 Mn |